IL-PROJECT44
30.4.2021 15:02:11 CEST | Business Wire | Press release
project44, the global leader in advanced visibility for shippers and logistics service providers will expand its real-time shipment tracking services in China – giving clients the same transportation visibility it offers across mature markets like North American and Europe. This expansion will focus the company’s resources on Asia-based visibility to fulfill its vision for global end-to-end visibility across all modes of transportation.
With logistics events in Asia continuing to send shockwaves across western markets, the opacity of Asia’s trucking markets has emerged as a weak link in global supply chains. As the economic recovery picks up pace, global supply chains are under pressure to improve agility, predictability, and efficiency.
At the same time, truckload markets in Asia have been modernizing rapidly as old trucks go out of service and China continues to incentivize the scrapping of old trucks. Newer trucks are equipped with electronic logging devices, paving the way to connect these trucks (with necessary data privacy provisions) to supply chain networks. These developments allow project44 to provide the foundational data needed to translate early indicators into important levers for supply chain resiliency.
Industry Support
The move by project44 to ramp up visibility in China has garnered broad support across the industry:
“Over the past year, Gartner has seen a dramatic increase in interest for Real-Time Transportation Visibility (RTTV) in the Asia Pacific,” said Bart A. De Muynck, Research Vice President, Transportation Technology at Gartner. “The sheer size of the Asia Pacific region combined with the diverse cultures spread across it creates unique challenges for transportation. Organizations that operate complex global supply chains often favor visibility solutions that can be implemented and utilized worldwide. project44 is recognized as a Leader by Gartner for its strong presence in both North America and Europe. Enterprise shippers that operate in Asia will benefit from project44’s expanded carrier coverage in China.”
“Building a more predictable global supply chain to increase on-time delivery and customer satisfaction is key to Lenovo’s business strategy,” said Renée Ure, Chief Operating Officer, Lenovo Infrastructure Solutions Group. “It’s critical to understand when materials are arriving from our suppliers to our factories across the world. project44’s expansion into the Asia Pacific region will give us further end-to-end visibility into our global supply chain to help us deliver on our promises to our customers.”
"CNHi is a truly global company in 180 countries. The recent state of global transportation has proven challenging, in part because it is difficult to manage our supply chains that span so many countries when disruption is high and visibility is so fragmented," said Dror Noach, Vice President of Global Logistics, CNH Industrial. "Gaining better visibility of both domestic and inbound flows going into our Asian manufacturing plants, especially China, could be quite beneficial for us. We believe project44's efforts to expand coverage in this region can help us improve assurance of supply and increase our efficiency."
Expanded Global Network Coverage
project44's best-in-class network already connects truckload carriers on every continent and nearly all containerized ocean freight moving between them, however, getting visibility into Asia’s trucking market remains a challenge for shippers. Its increased focus on Asian markets allows project44 to increase saturation outside of mature transportation markets and into Asia's ground transportation networks.
“At project44 we want to be wherever our customers need us, which means being connected to carriers all over the globe. For the first time ever, shippers can have a true global view of their supply chain network in a single platform,” said Jett McCandless, CEO and Founder of project44. “With our expansion into the Asia Pacific, we are considering the capabilities, regulations, and intricacies within each country which is key to delivering value to our current and future customers."
By expanding visibility in Asian markets, project44 will help buyers of Asian goods increase the resiliency of their supply chains. And in the process, project44 will extend visibility to domestic Asian shippers and logistics service providers who demand the same real-time transportation visibility enjoyed in western markets.
About project44
project44 solves some of the world’s most critical logistics challenges by connecting, automating, and providing real-time visibility into global transportation processes. With project44’s cloud-based platform, organizations can increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional, Amazon-like experience to their customers. project44 supports all transportation modes and shipping types, including air, parcel, final-mile, less-than-truckload, volume less-than-truckload, groupage, truckload, rail, intermodal, and ocean. To learn more, visit www.project44.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210430005100/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
